Compared with patients without OAC use, patients with prior FXa inhibitor or warfarin use were more likely to be older and non-Hispanic White and to have Medicare insurance; had a higher prevalence of cardiovascular risk factors, including atrial fibrillation or flutter, prior stroke, prior transient ischemic attack, coronary artery disease, peripheral vascular disease, diabetes, hypertension, heart failure, dyslipidemia, and obesity; and had lower a prevalence of tobacco and drug or alcohol abuse (Table 1). Here, F10 is linked to metabolic syndrome.